Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 10/20 | 0.81 |
| ▸ | DHFR | P00374 | 5/20 | 0.50 |
| ▸ | SLC19A1 | P41440 | 3/20 | 0.47 |
| ▸ | FPGS | Q05932 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6447840 | 1.00 | TYMS (0.81) | TYMSDHFRSLC19A1FPGS | |
| Osi-7904 SCHEMBL29692323 | 0.90 | TYMS (1.00) | TYMSDHFRSLC19A1 | |
| Osi-7904 SCHEMBL7207397 | 0.90 | TYMS (1.00) | TYMSDHFRSLC19A1 | |
| Osi-7904 SCHEMBL29692303 | 0.90 | TYMS (1.00) | TYMSDHFRSLC19A1 | |
| Osi-7904 SCHEMBL2195534 | 0.90 | TYMS (1.00) | TYMSDHFRSLC19A1 | |
| Osi-7904 SCHEMBL29389995 | 0.90 | TYMS (1.00) | TYMSDHFRSLC19A1 | |
| SCHEMBL6450938 | 0.88 | TYMS (0.65) | TYMSDHFRSLC19A1 | |
| SCHEMBL6446111 | 0.87 | TYMS (0.84) | TYMSDHFRSLC19A1FPGS | |
| SCHEMBL6446103 | 0.87 | TYMS (0.84) | TYMSDHFRSLC19A1FPGS | |
| SCHEMBL6450950 | 0.81 | TYMS (0.53) | TYMSDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855712-B2 | Combination of benzoquinazoline antifolates and protecting agents | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-15 | — | — | US | disclosed |
| US-20030203924-A1 | Novel combination of benzoquinazoline antifolates and protecting agents | SMITH GARY KEITH (US) | 2003-10-30 | — | — | US | disclosed |
| US-6579877-B2 | Reducing intestinal toxicity of a noncompetitive thymidylate synthase inhibitor by co-administering a folate derivative without blocking therapy; anticancer, antitumore agents | SMITHKLINE BEECHAM CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020137748-A1 | Novel combination of benzoquinazoline antifolates and protecting agents | SMITH GARY KEITH (US) | 2002-09-26 | — | — | US | disclosed |
| US-6358952-B1 | SIDE EFFECT REDUCTION WHEN ADMINISTERING NON-COMPETITIVE THYMIDYLATE SYNTHASE INHIBITOR AS ANTITUMOR AGENT | SMITHKLINE BEECHAM CORPORATION | 2002-03-19 | — | — | US | disclosed |
| EP-0675719-B1 | NOVEL COMBINATION OF BENZOQUINAZOLINE ANTIFOLATES AND PROTECTING AGENTS | WELLCOME FOUND (GB) | 1998-06-10 | — | — | EP | disclosed |
| US-5405851-A | Administering benzoquinazoline thymidylate synthase inhibitors | BURROUGHS WELLCOME CO. (US) | 1995-04-11 | — | — | US | disclosed |
| WO-1994014448-A1 | NOVEL COMBINATION OF BENZOQUINAZOLINE ANTIFOLATES AND PROTECTING AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203924-A1 | Novel combination of benzoquinazoline antifolates and protecting agents | SLC19A1, DHFR, FOLR2 | TYMS 20/4885DHFR 2/4885SLC19A1 1/4885 |
| US-20020137748-A1 | Novel combination of benzoquinazoline antifolates and protecting agents | SLC19A1, DHFR, FOLR2 | TYMS 20/4885DHFR 2/4885SLC19A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.